cyrilzakka/clinical-trials huggingface dataset:
AIS and START Grade With Films Transferring in Disaster Management

Disaster medical teams are formed by hospitals in response to the manpower needs of a large number of injured and sick patients. The current planning of hospitals for a large number of disaster medical manpower is too superficial. The application of today's inspection methods in the treatment of a large number of injured patients is not as good as it is. Therefore, understanding the scene situation has become the key point of manpower deployment. Today's internet transmission speed and computer artificial intelligence technology are very different from 9 years ago. The investigators adopt one more simple and easy-to-operate inspection method and use artificial intelligence technology to assist.

Disaster medical teams are formed by hospitals in response to the manpower needs of a large number of injured and sick patients. However, the current planning of hospitals for a large number of disaster medical manpower is too superficial. The application of today's inspection methods in the treatment of a large number of injured patients is not as good as it is. Therefore, understanding the scene situation has become the key point of manpower deployment. Today's network transmission speed and computer artificial intelligence technology are very different from 9 years ago. The image transmission of the communication software to understand the scene will help the hospital's manpower deployment or should the investigators adopt a more easy-to-operate inspection method and use artificial intelligence technology to assist Implementation method: 82 patients with a large number of injuries in the Ali mountain traffic accident over the years were included, medical records were reviewed. The photos of patients recorded at the hospital site and existing vital signs of the patients were mainly used to make grading of the traditional STAR triage and the AIS to understand the possible differences in image interpretation and injury detection. Excluding patients with incomplete clinical data of treatment, the statistical methods of the samples were Correlation analysis and Wilcoxon signed rank test, and the p value of statistical significance was 0.05

Eligibility Criteria:
Inclusion Criteria:

* All patients in the high mountain disaster

Exclusion Criteria:

* Excluding patients with incomplete clinical data of treatment and clinical films
Family Support Intervention in Intensive Care Units (The Four Supports Study)

The purpose of this study is to test the effectiveness of a multi-faceted communication intervention for family members of critically ill patients to reduce the family members' long-term symptoms of depression and anxiety.

One in four elderly Americans die in or shortly after discharge from an intensive care unit. An expanding body of literature documents that physician-family communication and end-of-life care is poor in intensive care units. These deficiencies are associated with high rates of adverse psychological outcomes among surrogates, physician-family conflict, and life support decisions that may be inconsistent with patients' goals and preferences. There is a lack on information on practical, generalizable interventions that effectively improve this important aspect of care for elderly patients and their families.

The primary aim of this study is to evaluate the effectiveness of a multifaceted communication intervention to improve psychological outcomes among family members of critically ill patients, using a randomized, controlled trial design.

Eligibility Criteria:
Inclusion Criteria for ICU Patients:

* must be unable to make treatment decisions for him/herself, as determined by the patient's physicians.
* must have have either an APACHE II score of ≥ 25 or, for patients with a primary neurologic diagnosis (e.g. intracranial hemorrhage, subdural hemorrhage, or subarachnoid hemorrhage), physician estimate that the patient has at least a 50% risk of long term, severe functional impairment
* must be 50 years old or greater.

Exclusion Criteria for ICU Patients:

* Patients who do not have surrogates or at least one family member who is willing to participate in the study.
* Patients awaiting organ transplantation.
Asian Diabetes Surgery Study (ADSS): Clinical Predictor for the Success of Metabolic Surgery

Type 2 Diabetes Mellitus (T2DM) is a serious health problem that has increased dramatically worldwide due to the high and increasing prevalence of obesity. Medical management of T2DM is of limited success. Because not well controlled T2DM patients are in high risk of blindness, cardiovascular accident and end staged disease, T2DM has become a major health burden for society. Recent data on the relative effectiveness of gastrointestinal metabolic surgery played as bariatric surgery in the remission of T2DM, suggests that it may be significantly more effective than current medical treatment. In considering that less than half of the T2DM patients can achieve satisfactory treatment goal under current medical treatment, gastrointestinal metabolic surgery shall play an important role in T2DM treatment in the future. However, the indication for metabolic surgery and clinical predictors of success are not clear now. These clinical predictors can help us to choose appropriate not-well controlled T2DM patients to receive metabolic surgery and reduce dverse health outcomes in those patients.

The present research proposal is designed to assess the clinical predictors of success in T2DM patients who receive metabolic surgery for the treatment of their diabetes. This study will recruit 200 obese T2DM patients who receive gastrointestinal metabolic surgery in our center and follow up them for one year. The Inclusion criteria are those with T2DM more than 6 months, age between 18 to 65 and HbA1C \> 8%. All the pre-operative clinical parameters will be collected prospectively, including C-peptide and stimulated C-peptide. The genetic polymorphism of these patients will also be analyzed and collected. The success of T2DM remission will be assessed at 12 months after metabolic surgery will be composite endpoint of CVD risk factor resolution; specifically, the proportion of patients with HbA1c \< 6.5%. The clinical predictors will be analyzed by uni-vriate and muti-variate analysis. In the first year project, we will included 100 patients and will include another 100 patients at the second year. This project will apply for the budget of 1st year.

Eligibility Criteria:
Inclusion Criteria:

* Age between 18 to 65.
* Type 2 DM \> 6 months, HbA1C\>8.0% under treatment
* Body mass index \>25 kg/m2
* could follow up

Exclusion Criteria:

* Age \<18 or \>65
* HbA1C \< 7%
* BMI \< 25 kg/m2
Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia

Neurodegenerative cerebellar ataxias represent a group of disabling disorders for which we currently lack effective therapies. Cerebellar transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been demonstrated to modulate cerebellar excitability and improve symptoms in patients with cerebellar ataxias. In this randomized, double-blind, sham-controlled study, the investigators will evaluate whether a two-weeks' treatment with cerebellar anodal tDCS and spinal cathodal tDCS can improve symptoms in patients with neurodegenerative cerebellar ataxia and can modulate cerebello-motor connectivity, at short and long term.

Neurodegenerative cerebellar ataxias represent a heterogeneous group of disabling disorders in which progressive ataxia of gait, limb dysmetria, oculomotor deficits, dysarthria and kinetic tremor are the prominent clinical manifestations. Both the hereditary and sporadic forms usually present in young adulthood, and are characterized by atrophy of cerebellar or brainstem structures. Currently, cerebellar ataxia lack effective disease-modifying therapies.

Cerebellar transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been demonstrated to modulate cerebellar excitability and improve symptoms in patients with cerebellar ataxias. The present randomized, double-blind, sham-controlled study will investigate whether a two-weeks' treatment with cerebellar anodal tDCS and spinal cathodal tDCS can improve symptoms in patients with neurodegenerative cerebellar ataxia and can modulate cerebello-motor connectivity, at short and long term.

Subjects will be randomized in two groups, one receiving a 10 day (5 days/week for 2 weeks) treatment with anodal cerebellar and cathodal spinal tDCS and the other receiving sham stimulation with identical parameters. After the intervention, patients will be reassessed with a clinical and neurophysiological evaluation at 2 weeks, 1 months and 3 month after treatment.

Eligibility Criteria:
Inclusion Criteria:

* Patients with a cerebellar syndrome and quantifiable cerebellar atrophy

Exclusion Criteria:

* Severe head trauma in the past
* History of seizures
* History of ischemic stroke or hemorrhage
* Pacemaker
* Metal implants in the head/neck region
* Severe comorbidity
* Intake of illegal drugs
* Pregnancy
Wireless Monitoring for Clinical Deterioration

The study evaluates whether implementing a wireless monitoring system for patients admitted to hospital wards reduces mortality and cardiopulmonary failure.

The trial is designed as a stepped-wedge cluster RCT. Hospital wards (which constitute clusters in this design) will be randomized to have wireless monitoring, 7 wards at a time, with each 7 wards constituting a sequence. The study consists of 5 periods of two-month sequences followed by a one-month transition time with a phased introduction of the intervention. In the first period, all wards will have no wireless monitoring. After a baseline period of 2 (+1 washout) months, the intervention (monitoring system) will be implemented in a randomly selected new sequence every 3-month period until the intervention is implemented in all sequences.

Eligibility Criteria:
Inclusion Criteria:

Ward level Inpatient wards, defined as wards used to manage adult inpatients.

Patient level

1. Aged 14 years or older
2. Checked in as inpatient status to one of the study wards

Exclusion Criteria:

Ward level

1. Cardiology, pediatric, obstetric wards
2. ICUs and emergency departments
3. Operating rooms
4. Outpatient clinics
5. Daycare wards, endoscopy, outpatient procedure areas, hemodialysis units

Patient level No commitment for full life support at the time of arrival to the study ward (designated as Do-Not-Resuscitate status)
Comparison of Senofilcon A Toric Lenses to Balafilcon A Toric Lenses Over Extended Wear Period

To evaluate two toric contact lenses on the ocular physiology of existing contact lens wearers when used in an extended wear modality of days/six nights.


Eligibility Criteria:
Inclusion Criteria:

* Able to wear study lenses in parameters available
* Non-presbyopes between the ages of 18-45
* Understand and sign informed consent
* Willing to follow the protocol
* Achieve at least 20/30 (6/9) visual acuity (VA) in right eye (OD) and left eye (OS) with study lenses
* Myopia -0.75 to -6.25, cylinder -0.75 to -1.50 diopters (D) (axis 90 +/- 15, 180 +/- 15) or -1.75 D (axis 90 +/- 10, 180 +/- 10)
* Adapted soft contact lens wearer
* Swims no more than once a week
* Has a wearable pair of spectacles.

Exclusion Criteria:

* Any ocular or systemic disorder which may contraindicate contact lens wear
* Any topical ocular medication
* Aphakic
* Corneal refractive surgery
* Corneal distortion from hard CL wear or keratoconus
* Pregnant or lactating
* Grade 2 or worse slit lamp signs
* Infectious disease
* Previous clinical study within 2 weeks
* Don't agree to participate
* Polymethyl methacrylate (PMMA) or rigid gas-permeable (RGP) lens wear in last 8 weeks
* Previous adverse effects that contraindicate extended lens wear.
* Self-reported symptoms of itchiness or scratchiness with habitual lenses.
The Effect of Home-Based Telerehabilitation in Individuals With Stroke

Stroke is a clinical picture that develops due to occlusion or rupture of cerebral vessels and results in loss of cerebral functions. Stroke individuals face some limitations in managing daily activities such as walking, dressing, feeding and showering. Personal, environmental, and societal limitations have led to the development of new treatment strategies, such as telerehabilitation(TR), to meet the needs of stroke individuals and their caregivers.

In this study, patients will be randomized and divided into 2 groups in order to examine the effects of two different TR methods on physical parameters and activities of daily living in stroke patients. Baseline assessments will be made for both groups to determine functionality, activities of daily living, fall activity, quality of life, and level of fatigue. For 8 weeks, the TR group will do their exercises with exercise videos prepared on the system 3 times a week. The control group, on the other hand, will do their exercises with exercise brochures on the system 3 times a week for 8 weeks. After 8 weeks, assessments will be repeated. With telerehabilitation to be applied to individuals with stroke, it is aimed to increase functional capacity, independence in daily living activities and quality of life, and reduce the number of falls and fatigue levels.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with stroke at least 1 year ago by a neurologist
* Modified Rankin score ≤3
* Have an internet infrastructure that can be accessed at home
* Not participated in a standardized physiotherapy program in the past 3 months

Exclusion Criteria:

* Presence of blurred or low vision problems
* Hearing and speech impairment at a level that will affect participation in the system
* Epilepsy
* Presence of pregnancy
* Having any cognitive problems that prevent using the system
Control of Major Bleeding After Trauma Study

Bleeding is the most avoidable cause of death in trauma patients. Up to one-third of severely injured trauma patients are found to be coagulopathic and forty percent of the mortality following severe injury is due to uncontrollable hemorrhage in the setting of coagulopathy. It has been established that early administration of fresh frozen plasma decreases mortality following severe injury, replacing lost coagulation factors, improving the coagulopathy and restoring blood volume. This study will determine if giving plasma to severely injured trauma patients during ambulance transport versus after arrival to the hospital will help reduce hemorrhage, thus decreasing both total blood product administration and mortality.

Study Design: Severely injured trauma patients with a systolic blood pressure (SBP) ≤ 70 or SBP ≤ 90 with a heart rate ≥ 108 bpm at the scene will be enrolled and randomized to receive either 2 units of frozen plasma thawed in the field or normal saline (the current standard of care), as the initial resuscitation fluid. After this initial resuscitation fluid, both groups will receive the same standard of care, including packed red blood cells, additional normal saline, or plasma as needed based on laboratory and clinical evidence of coagulopathy. Blood samples and clinical information will be collected throughout the hospital stay up to 28 days after injury.

Eligibility Criteria:
Inclusion Criteria:

* Age\>=18 years
* Acutely injured
* SBP\<70 mmHg or SBP 71-90 mmHg with heart rate (HR)\>108 beats per minute.

Exclusion Criteria:

* Visibly or verbally reported pregnant women
* known prisoners
* unsalvageable injuries (defined as asystolic or cardiopulmonary resuscitation prior to randomization)
* known objection to blood products
* the patient has an opt-out bracelet or, necklace or wallet card
* a family member present at the scene objects to the patient's enrollment in research.
Prodromal Parkinsonian Features in GBA1 Mutation Carriers

Objective of the trial. To define a sub-population which is at increased risk of developing Parkinson, beyond the fact of carrying Gaucher; in this sub-population the investigators shall conduct a comprehensive evaluation that includes a variety of non-invasive tests, whose purpose is to evaluate the state of the pre- Parkinson's disease signs, signs which can appear, even twenty years before the appearance of the disease, and also to compare them to a group of diagnosed Gaucher patients and a group of healthy people who are not carriers of Gaucher disease.

A group of those carriers will be available for trial or for treatment, if there will be a medicine for the prevention of the development of Parkinson, obtainable.

The carriers, the healthy people and the Gaucher patients will undergo a number of non-invasive tests, which test the pre-Parkinson signs.

The tests are based on various sense tests, blood tests, measuring of blood pressure, lying and standing, ultra-sound of the brain and a neurological test (test of the nervous system and various questionnaires).

Eligibility Criteria:
Inclusion Criteria:

* Willing to participate

Exclusion Criteria:

* PD patients
* Dementia
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia (AML).

The Phase 1 will consist of a dose escalation of evorpacept (ALX148) in combination with venetoclax and azacitidine to evaluate safety and tolerability, and to identify the recommended Phase 2 dose of evorpacept (ALX148) in combination with venetoclax and azacitidine. The Phase 2 will evaluate the efficacy of evorpacept (ALX148) in combination with venetoclax and azacitidine for patients with AML. While intended to be a Phase 1/2 clinical study, the study never moved forward to Phase 2.

Eligibility Criteria:
Inclusion Criteria:

* Cytologically or histologically confirmed diagnosis of relapsed/refractory or newly diagnosed AML per WHO 2016 classification.
* Phase 1a: AML that is relapsed/refractory or that is previously untreated in patients not considered suitable for intensive induction therapy.
* Phase 1b: AML that is relapsed/refractory after prior treatment with a HMA-based regimen.
* Phase 2: Previously untreated AML in patients who are not considered suitable candidates for intensive induction therapy.
* Adequate renal and liver function.
* Age ≥18 years.
* Adequate performance status.

Exclusion Criteria:

* In Phase 1a and 1b, patients that have undergone prior allo-HSCT must be at least 3 months post-HSCT, without uncontrolled graft-versus-host disease (GVHD). For Phase 2, patients that have undergone prior allo-HSCT are excluded.
* Patients with newly diagnosed AML with favorable risk cytogenetics such as t(8;21), inv(16), or t(16;16) as per the NCCN Guidelines Version 3, 2019 for AML.
* Patients with acute promyelocytic leukemia (APL).
* Prior treatment with any anti-CD47 or anti-SIRPalpha (signal regulatory protein alpha) agent.
* Known active viral infections, including hepatitis B and C, human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS) related illness, or SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer

This study aims at developing an accurate, simple, and cost-effective method for screening and early detection of uterine cancers

The present study aims at developing an accurate, simple and cost-effective method for screening and early detection of uterine cancers in women using novel inventions and biotechnology methods for collection and assay of uterine cells. Results of P2X7 assays using tissues obtained from women with known uterine cancer and from women with histologically normal endometrium will be compared. These data will also serve as basis for future studies to test the predictive value of the method in population-based studies.

Eligibility Criteria:
Inclusion Criteria:

* women scheduled to undergo hysterectomy
* ages 18 years and older

Exclusion Criteria:

* pregnant women
* students or employees under the direct supervision on the investigators.
A Pharmacokinetic and Bioavailability Study of Mannitol for Inhalation Using Normal Subjects

The study has an open-label, randomized, crossover design, in which each subject will receive mannitol powder for inhalation using a dry powder inhaler with and without premedication with a bronchodilator, mannitol powder for inhalation in capsules administered orally, and mannitol in a commercial formulation designed for intravenous use.


Eligibility Criteria:
Inclusion Criteria:

* Subject has signed a written informed consent form.
* Subject is a normal male volunteer between 18 and 65 years of age.
* Subject is willing to comply with the procedures of the study and to remain in the clinical unit for the scheduled visits.
* Subject is willing to abstain from chewing gum for the duration of the study.

Exclusion Criteria:

* Subject has asthma or other disease affecting the lungs or airways.
* Subject has a history indicating possible airway hyperresponsiveness.
* Subject is allergic to mannitol or gelatin or a known intolerance to intravenous mannitol.
* Subject uses inhaled drugs (legal or illegal).
* Subject uses oral bronchodilator drugs.
* Subject has celiac disease, Crohn's disease or other disease affecting intestinal absorption.
* Subject has renal impairment or other condition that would affect urine collection.
* Subject's weight deviates by more than 15% from the ideal weight listed for his height in the Metropolitan Life table.
* Subject is a smoker.
* Subject has participated in another clinical trial within the past 30 days.
* Subject has used chewing gum within the past 72 hours.
* Subject needs to use bisphosphonates, non-steroidal anti-inflammatory agents, or other drugs known to affect intestinal permeability on a chronic basis.
* Subject has used non-steroidal anti-inflammatory agents within the past 72 hours
Placebo Modulation of Orthodontic Pain

How placebo modulates orthodontic pain remains largely unknown. The present study aimed to investigate the placebo modulation of brain activity associated with orthodontic pain using fMRI.

How placebo modulates orthodontic pain remains largely unknown. The present study aimed to investigate the placebo modulation of brain activity associated with orthodontic pain using fMRI. 23 voluneers were recruited in a longitudinal fMRI experiment. At both the baseline and the one-month follow-up, orthodontic separators were placed between right lower molars 24 hours before MRI scans. At baseline, the subjects were scanned without placebo while all subjects took placebos half an hour before the scan at follow-up. Scans include a bite/non-bite task fMRI and a followed resting state fMRI. A generalized linear model was used to identify pain-regulating network from task fMRI, and functional connectivity analysis of pain related brain regions was performed to study the possible modulation of placebo on connectivity of pain-regulating networks using resting-state fMRI.

Eligibility Criteria:
Inclusion Criteria:

* Female, 20-25 years old;
* Right handed;
* Understand the Visual Analog Scale;
* No history of serious illness, surgery, psychiatric disorders or neurological;
* No history of drug or alcohol abuse;
* No Maxillofacial diseases, agomphiasis, caries, metal filling material or crown;
* Individual normal occlusion with no orthodontic treatment history.

Exclusion Criteria:

* claustrophobic or experienced obvious adverse reactions including fear, nausea, vomiting
* discomfort during the scan process or during menstruation.